Every year more than 300,000 patients undergo heart valve surgery in the United States. Arbor has initiated human clinical trials of its core products in select European centers during 2005. Arbor expects clinical trial activity in U.S. institutions will commence in early 2008. If you are a physician interested in trial participation, please contact Dave Schickling for more information.   Benefits of Arbor System Approach Simpler for both Standard & “Re-do” operations May allow smaller incisions Faster (11 min. in animal experiment) Better flow dynamics – inflow and outflow No suture tails or pledgets   Arbor Surgical Technologies © 2005, All Rights Reserved